Evolving standards of care and new challenges in the management of HER2‐positive breast cancer

The management of human epidermal growth factor receptor (HER2)–positive breast cancer (BC) has rapidly evolved over the last 20 years. Major advances have led to US Food and Drug Administration appr…

Read the full article here

Related Articles